1. Home
  2. EXAS vs BCH Comparison

EXAS vs BCH Comparison

Compare EXAS & BCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • BCH
  • Stock Information
  • Founded
  • EXAS 1995
  • BCH 1893
  • Country
  • EXAS United States
  • BCH Chile
  • Employees
  • EXAS N/A
  • BCH 12217
  • Industry
  • EXAS Medical Specialities
  • BCH Commercial Banks
  • Sector
  • EXAS Health Care
  • BCH Finance
  • Exchange
  • EXAS Nasdaq
  • BCH Nasdaq
  • Market Cap
  • EXAS 11.6B
  • BCH 11.7B
  • IPO Year
  • EXAS N/A
  • BCH 2002
  • Fundamental
  • Price
  • EXAS $59.25
  • BCH $23.09
  • Analyst Decision
  • EXAS Strong Buy
  • BCH Hold
  • Analyst Count
  • EXAS 16
  • BCH 1
  • Target Price
  • EXAS $72.80
  • BCH $21.00
  • AVG Volume (30 Days)
  • EXAS 2.2M
  • BCH 295.6K
  • Earning Date
  • EXAS 11-05-2024
  • BCH 02-03-2025
  • Dividend Yield
  • EXAS N/A
  • BCH 7.27%
  • EPS Growth
  • EXAS N/A
  • BCH 14.90
  • EPS
  • EXAS N/A
  • BCH 0.02
  • Revenue
  • EXAS $2,692,328,000.00
  • BCH $3,231,399,879.00
  • Revenue This Year
  • EXAS $11.81
  • BCH N/A
  • Revenue Next Year
  • EXAS $11.41
  • BCH $1.83
  • P/E Ratio
  • EXAS N/A
  • BCH $7.39
  • Revenue Growth
  • EXAS 11.91
  • BCH 10.24
  • 52 Week Low
  • EXAS $40.62
  • BCH $20.93
  • 52 Week High
  • EXAS $79.62
  • BCH $25.97
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 48.86
  • BCH 47.96
  • Support Level
  • EXAS $61.28
  • BCH $23.15
  • Resistance Level
  • EXAS $62.15
  • BCH $23.74
  • Average True Range (ATR)
  • EXAS 2.02
  • BCH 0.27
  • MACD
  • EXAS 0.15
  • BCH 0.05
  • Stochastic Oscillator
  • EXAS 3.39
  • BCH 54.29

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About BCH Banco De Chile ADS

Operating under three separate brand names (Banco de Chile, Banco Edwards-Citi, and Banco CrediChile) Banco de Chile is the second largest in the country by loans and third largest by deposits. Banco de Chile generates most of its net interest income (roughly 60% of total revenue) from its mortgage, unsecured consumer credit lines, and commercial loans, with 25% of its outstanding loans being made to firms with more than 10,000 million CLP in revenue. Outside of its banking business, Banco de Chile is the largest asset manager in the country and one of the largest security brokerages, supporting its substantial fee-based revenue.

Share on Social Networks: